Oxford Cancer Biomarkers announces first patient into its clinical study for its precision oncology OncoProg test for colorectal cancer

OXFORD, UK – 14th January 2025 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully met a major milestone with recruitment of the first patient into the clinical utility study of its precision oncology…